Tvardi Therapeutics, Inc. (TVRD)

Market Cap	48.39M
Revenue (ttm)	n/a
Net Income (ttm)	-23.63M
Shares Out	9.38M
EPS (ttm)	-3.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	450,017
Open	5.25
Previous Close	5.23
Day's Range	4.91 - 5.35
52-Week Range	4.91 - 43.65
Beta	n/a
Analysts	Buy
Price Target	51.67 (+901.36%)
Earnings Date	Nov 21, 2025

About TVRD

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: TVRD
• Website: https://tvarditherapeutics.com

Analyst Summary

According to 7 analysts, the average rating for TVRD stock is "Buy." The 12-month stock price target is $51.67, which is an increase of 901.36% from the latest price.

Price Target

$51.67

(901.36% upside)

Analyst Consensus: Buy